Takeda gains novel drug discovery tech through Envoy acquisition
This article was originally published in Scrip
Executive Summary
Takeda's late 2010 research alliance with Envoy Therapeutics has led to the Japanese firm acquiring 100% of the privately held US CNS drug discovery specialist for up to $140 million in cash, in a deal expected to be finalized within the next few days.